 |
|
An Inter-Ethnic Comparison Study of Ziprasidone Plasma Levels, Dosage and Clinical Response in Patients with Schizophrenia
Dongsheng Lv, Meirong Zhao, Lixia Chen, Dongsheng Yu, Xiaobin Yun, Qing Yang, Xiaojun Huang
Psychiatry Investig. 2017;14(3):360-367. Published online 2017 May 16 DOI: https://doi.org/10.4306/pi.2017.14.3.360
|
|
Ziprasidone population pharmacokinetics and co-medication effects in Chinese patients
Shuang Bao, Siyu Yang, Zixin Hua, Jiqian Li, Yannan Zang, Xingang Li
Naunyn-Schmiedeberg's Archives of Pharmacology.2024;[Epub] CrossRef Optimisation of pharmacotherapy in psychiatry through therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests: focus on antipsychotics
XM Hart, G Gründer, N Ansermot, A Conca, E Corruble, S Crettol, P Cumming, G Hefner, A Frajerman, O Howes, M Jukic, E Kim, S Kim, I Manisalco, S Moriguchi, DJ Müller, S Nakajima, M Osugo, M Paulzen, HG Ruhe, M Scherf-Clavel, G Schoretsanitis, A Serretti,
The World Journal of Biological Psychiatry.2024; : 1. CrossRef Racial/Ethnic Differences in the Pharmacokinetics of Antipsychotics: Focusing on East Asians
Shih-Ku Lin
Journal of Personalized Medicine.2022; 12(9): 1362. CrossRef Efficacy and safety of lurasidone in acutely psychotic patients with schizophrenia: A 6‐week, randomized, double‐blind, placebo‐controlled study
Masaomi Iyo, Jun Ishigooka, Masatoshi Nakamura, Reiko Sakaguchi, Keisuke Okamoto, Yongcai Mao, Joyce Tsai, Alison Fitzgerald, Tadashi Nosaka, Teruhiko Higuchi
Psychiatry and Clinical Neurosciences.2021; 75(7): 227. CrossRef Inter‐ethnic differences in pharmacokinetics—is there more that unites than divides?
Olusola Olafuyi, Nikita Parekh, Jacob Wright, Jennifer Koenig
Pharmacology Research & Perspectives.2021;[Epub] CrossRef
|